Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-08-19
    E.g., 2018-08-19

Archive Search

Pages

38 results
3:47 PM, Apr 24, 2018  |  BC Extra | Company News

Amgen considering risk-based Aimovig pricing

On a conference call to discuss 1Q18 earnings call, Amgen Inc. (NASDAQ:AMGN) EVP of Global Commercial Operation Anthony Hooper said the biopharma is "prepared to talk to payers about risk-based contracts with Aimovig." This quarter, Amgen...
2:16 PM, Apr 24, 2018  |  BC Extra | Company News

Biogen looks to ex-U.S. markets for growth

Biogen Inc. (NASDAQ:BIIB) perceives greater long-term growth opportunities than anticipated in the EU and emerging markets, the company's CEO Michel Vounatsos said on its earnings call Tuesday, while noting that the U.S. market remains its...
7:50 AM, Apr 06, 2018  |  BC Week In Review | Company News  |  Other News

Samsung Bioepis, AbbVie settle Humira biosimilar dispute

Samsung Bioepis Co. Ltd. and AbbVie Inc. (NYSE:ABBV) agreed to settle all litigation related to AbbVie's Humira adalimumab in a deal that will allow Samsung Bioepis to launch its biosimilar of the autoimmune drug, Imraldi...
3:09 PM, Apr 05, 2018  |  BC Extra | Company News

Samsung Bioepis, AbbVie settle Humira biosimilar dispute

Samsung Bioepis Co. Ltd. and AbbVie Inc. (NYSE:ABBV) agreed to settle all litigation related to AbbVie's Humira adalimumab in a deal that will allow Samsung Bioepis to launch its biosimilar of the autoimmune drug, Imraldi...
4:10 PM, Oct 06, 2017  |  BioCentury | Finance

Coasting on catalysts

NASDAQ:NBIX) / AbbVie Inc. (NYSE:ABBV) Elagolix Endometriosis Pivotal trial data 4Q17 Novartis AG (NYSE:NVS; SIX:NOVN) Biosimilar adalimumab
8:15 AM, Sep 01, 2017  |  BC Week In Review | Clinical News  |  Regulatory

EC approves Bioepis' Humira biosimilar

biosimilars. Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass.  Samsung BioLogics Co. Ltd. (KOSDAQ:207940), Seoul, South Korea  Product: Biosimilar adalimumab
5:20 PM, Jul 07, 2017  |  BioCentury | Finance

A clinical quarter

ASX:MSB; NASDAQ:MESO) MSC-100-IV Acute graft-versus-host disease (GvHD) Ph III data 2H17 Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) Biosimilar adalimumab
myopathy (GNEM)/hereditary inclusion body myopathy (HIBM) Ph III Ace-ER data 2H17 Novartis AG (NYSE:NVS; SIX:NOVN) Biosimilar adalimumab
12:07 PM, Jul 03, 2017  |  BC Week In Review | Clinical News  |  Regulatory

CHMP recommends Imraldi biosimilar adalimumab

EMA’s CHMP recommended approval of Imraldi biosimilar adalimumab (SB5) from Samsung Bioepis Co. Ltd. to treat psoriasis …
Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J.  Samsung Group , Seoul, South Korea  Product: Imraldi biosimilar adalimumab
3:38 PM, Jun 23, 2017  |  BC Extra | Company News

CHMP recommendations include two new HCV combos

and CDK6 inhibitor in the indication in March. The committee also backed approval of Imraldi biosimilar adalimumab
12:51 PM, Jun 09, 2017  |  BC Week In Review | Clinical News  |  Regulatory

EMA accepts MAA for Humira biosimilar from Fujifilm, Kyowa

Fujifilm Holdings Corp. (Tokyo:4901), Tokyo, Japan  Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan  Product: Biosimilar adalimumab

Pages